Lavior Fortifies US Supply Chain with Major Wound Care Expansion

MIAMI, FL – February 09, 2026 – In a strategic move to counter a volatile healthcare market, U.S.-based wound care company Lavior today announced a multi-faceted expansion designed to bolster supply chain stability and enhance patient care. The initiative includes a significant increase in domestic manufacturing capacity, the launch of two distinct product portfolios for professional and consumer markets, and a complete brand overhaul.

The announcement comes at a critical time for the global wound care industry. Valued at nearly $21 billion in 2024, the market is projected to surge past $30 billion by 2030, driven by an aging population and the dramatic rise of chronic conditions like diabetes. However, this growth is shadowed by persistent challenges, including fragile supply chains, inconsistent product availability, and shifting clinical standards—issues that Lavior aims to address directly with its new strategy.

Reshoring for Resilience: A Bet on Domestic Manufacturing

At the core of Lavior's announcement is the expansion of its U.S.-based manufacturing facility. This move is a direct response to the supply chain vulnerabilities that have plagued the medical device sector, which were starkly exposed during the COVID-19 pandemic. By increasing domestic production, the company aims to insulate itself and its customers from global disruptions, tariffs, and the periodic shortages that have affected essential products, including honey-based wound care items.

Production will be scaled up under the company's existing ISO 13485–certified quality management system, a rigorous international standard for medical device manufacturing. This ensures that increased capacity does not come at the expense of quality, providing healthcare systems with a dependable source of clinically validated products.

"Wound care is undergoing meaningful change, from supply chain pressure to evolving clinical expectations," said Gilad Savion, CEO of Lavior, in a statement. "Expanding U.S.-based manufacturing allows us to remain a reliable source of solutions informed by clinical research and best practices and to support continuity of care when consistency matters most."

This commitment to domestic production aligns with a broader industry trend toward nearshoring and reshoring to create more resilient supply networks. For hospitals and clinics grappling with unpredictable inventory and rising patient loads, a stable domestic supply of wound care solutions represents a significant advantage in ensuring uninterrupted patient treatment.

A Tale of Two Portfolios: Segmenting Care for Clinic and Consumer

Recognizing the different needs of healthcare professionals and the general public, Lavior is rolling out a dual-portfolio model. This strategy creates a clear distinction between its clinical and consumer offerings while maintaining a unified quality standard.

The Lavior Professional Portfolio is designed exclusively for clinical environments such as hospitals, wound care centers, and private clinics. These products will be offered in clinical-use sizes and distributed solely through authorized professional channels, ensuring that healthcare providers have access to formulations and formats optimized for their demanding workflows and patient populations.

In parallel, the company will continue to build its direct-to-consumer line, which makes its science-backed formulations accessible for everyday skin and wound care needs at home. This is particularly relevant as healthcare increasingly shifts toward outpatient and home-based settings. By developing its consumer products under the same stringent quality systems as its professional line, Lavior aims to create a continuum of care, allowing for brand consistency from the hospital to the home.

This dual-market approach is a savvy business move in a competitive landscape. It allows the company to address the entire patient journey and capture market share in both the high-volume clinical sector and the rapidly growing consumer health space.

Beyond Scar Repair: A 'Care-First' Philosophy in Action

Underpinning the product strategy is what Lavior calls its "care-first philosophy." This approach emphasizes proactive support for the skin's natural healing environment during the earliest stages of wound and post-procedural recovery. Instead of focusing solely on correcting scars after they have formed, the company's formulations are designed to optimize conditions for healing from the outset.

A prime example is the Post-Surgical and Post-Procedure Skin Barrier Gel, which is formulated to support the skin's recovery process immediately following interventions. This clinical philosophy is well-aligned with modern wound care science, which increasingly focuses on creating an optimal healing environment to prevent complications and improve outcomes.

This focus is critical in addressing the market's most pressing challenges, particularly the management of chronic wounds like diabetic foot ulcers and pressure ulcers. With over 500 million people living with diabetes worldwide—a number expected to more than double in the next 30 years—the demand for effective, evidence-based wound care is exploding. Lavior's emphasis on science-backed solutions positions it to meet the needs of this growing and vulnerable patient population.

A New Look for a New Era

Complementing the operational and product-line changes is a comprehensive brand and packaging refresh. The new visual identity features a cleaner, more modern aesthetic intended to reflect the company's evolution and scientific foundation. While the formulations inside the packaging remain the trusted ones used by clinicians and consumers, the updated look is designed to enhance brand recognition and appeal across both professional and retail channels.

This rebrand is more than cosmetic; it's a signal to the market that Lavior is entering a new phase of strategic growth. With its supply chain fortified, product lines clarified, and brand identity refreshed, Lavior is not just reacting to a turbulent market but is actively shaping its role within it. The company's integrated strategy of domestic production and dual-market focus appears designed to build resilience and foster growth, positioning it as a key player in the future of wound and skin care for years to come.